After bagging Shire’s cell therapy castoff, Caladrius stock climbs
After Shire’s $32 billion buyout of Baxalta back in 2016, the company has been purging its unwanted assets to biotechs with barren pipelines. Now, one of those programs is landing in familiar hands.
Caladrius Biosciences $CLBS, a biopharma that killed its lead drug two years ago, has snatched an exclusive license to a late-stage cell therapy program being tossed by Shire. The program is a CD34+ cell therapy for refractory angina, and it’s a treatment Caladrius’ CMO knows quite well.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.